Navigation Links
China Cord Blood Corporation Announces Cancellation of Nine Million Management Incentive Warrants

HONG KONG, July 15 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO; "the Company") today announced the cancellation of its nine million management incentive warrants plan, which was approved prior to the business combination in 2008. The Company took this action to further align executive compensation with shareholder interests. In return, the Company may consider a more conventional scheme to reward its management team for their outstanding performance in the forthcoming year.

Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation, commented, "We have exceeded our target to grow the subscriber bases by 30% in the past two years and are committed to increase our subscriber base by no less than 30 percent, or at least 58,000 new subscribers in fiscal year 2011. After considering the dilutive impact to our shareholders under the nine million management incentive warrant plan, we decided to cancel such plan and are considering having a more conventional scheme to align management interests with shareholders."

Ms. Zheng concluded, "We believe management interests are in line with shareholders and our outstanding performance is the best way to reward our shareholders."

About China Cord Blood Corporation

China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses have been issued as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at .

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    China Cord Blood Corporation
     Ms. Joeling Law
     Tel:   +852-3605-8180

    ICR, LLC
     In New York:
     Ashley M. Ammon or Christine Duan
     Tel: +1-646-277-1227

     In Beijing:
     Wen Lei Zheng
     Tel: +86-10-6599-7968

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
(Date:10/12/2015)... October 12, 2015 LabStyle Innovations ... Management Solution, today announced its Medical Director, Dr. ... at MobiHealth,s 5th EAI International Conference on Wireless ... through innovations in mobile and wireless technologies," the conference ... from October 14 - 16, 2015. The conference ...
(Date:10/12/2015)... ... , ... NeuMedics Inc., is a specialty biopharmaceutical company focused on identifying and ... be administered as an eye drop, announced today it has been selected to present ... place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio. The ...
(Date:10/10/2015)... Oktober, 2015 Am 8. Oktober hat ... Partei für Kalifornien) ihre Würdigung der International Plasma ... die Aufzeichnungen des Kongresses eintragen lassen. Die IPAW ... (PPTA) und ihren Mitgliedsunternehmen unterstützt. Ihre Ziele ... Bewusstseins über Plasmaspenden weltweit , Würdigung des ...
(Date:10/9/2015)... 9, 2015  DePuy Synthes Trauma* announced today the ... ®  Technology**, the only pre-hydrated demineralized cancellous bone ... (foot and ankle, hand and wrist), including fusion, and ... at the 2015 Orthopaedic Trauma Association (OTA) Annual Meeting. ... for new bone growth) and osteoinductive 2,3 (stimulates ...
Breaking Biology Technology:
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
(Date:9/26/2015)... 2015  Results of a TactioRPM pilot project ... at the Stanford Medicine X Conference. In a ... Connected Health Devices and Pharmacogenomics", Roger Simard ... explain how senior patients equipped with connected health ... via the TactioRPM remote patient monitoring platform were ...
(Date:9/10/2015)... 2015 Report Details Emerging ... Opportunities and Revenue Prospects to Help You Stay ... especially new drug classes? Get the latest technological ... exclusive market data and industry knowledge, benefitting your ... opportunities and sales predictions. Visiongain,s new study ...
Breaking Biology News(10 mins):